Pricing Log in Create free account
Saturday 17 October 2026 Export CHE’s income statement to Excel — free account

Chemed Corporation

CHE Healthcare Medical Care Facilities

Chemed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 4.06% from fiscal 2024. In the quarter to June 2026, revenue grew 8.80%, EPS grew 42.8% and free cash flow fell 43.5%, each against the same quarter a year earlier. Dividend growth for twenty-five consecutive years, revenue growth for three.

512.38 3.06 −0.59%
Market cap
$6.7B
P/E
25.7×
Fwd P/E
20.4×
Dividend yield
0.49%
F-score
6/9
Altman Z
11.69
Beneish M
−2.76
Dividend safety
100/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 8.76
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 — — — 2 — 3 1 1 3 2 —
Insider Ownership 2.69%

Capital & Financial Ratios $m

Market Cap 6,740.00
Revenue 2,595.00
Net Income 274.99
Free Cash Flow 328.12
Net Debt 99.78
Current Ratio 0.91 (below 1: weak)
Debt/Equity 0.17 (at or below 0.5: strong)
P/E ratio 25.71
Fwd P/E 20.40
P/S ratio 2.60
P/B ratio 8.13 (above 6: high)
Past 5Y EPS Growth (1.20%) (below 0%: weak)
This Y EPS Growth 18.30% (at or above 15%: strong)
Next Y EPS Growth 7.94%
Next Y revenue growth 7.55%
Next 5Y EPS Growth 11.95%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.6×, against a ten-year median of 3.4×; over the ten years it ranged from 1.5× in 2016 to 4.2× in 2024.
P/E against its own 10 years 34.54%
10-year low 10-year high
P/S against its own 10 years 29.60%
10-year low 10-year high
P/B against its own 10 years 47.62%
10-year low 10-year high
EV/Sales against its own 10 years 30.85%
10-year low 10-year high
EV/FCF against its own 10 years 30.70%
10-year low 10-year high

Dividends

Payout Ratio 0.13
Annual Dividend Rate 2.50
Annual Dividend Yield 0.49%
total individual payouts
2028 Powerpack
2027 Powerpack
2026 2.43
0.60
0.60
0.70
2025 2.20
0.50
0.50
0.60
0.60
2024 1.80
0.40
0.40
0.50
0.50
2023 1.56
0.38
0.38
0.40
0.40
2022 1.48
0.36
0.36
0.38
0.38
2021 1.40
0.34
0.34
0.36
0.36
2020 1.32
0.32
0.32
0.34
0.34
2019 1.24
0.30
0.30
0.32
0.32
2018 1.16
0.28
0.28
0.30
0.30
2017 1.08
0.26
0.26
0.28
0.28
2016 1.00
0.24
0.24
0.26
0.26
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 264 178 75 40
Receivables 182 171 183 189
Inventory 12 8 8 8
Other — — — —
501 395 303 291
2023 2024 2025 Q'26
Payables 64 44 64 85
ST’ Debt — — — —
Other 56 43 59 58
312 286 287 320

Compound Annual Growth %

10y 5y 3y
Sales 5.07% 4.00% 5.82%
Cash Flow 8.51% (4.52%) 7.81%
Earnings 9.17% (3.65%) 2.04%
Book Value 6.68% 1.68% 7.03%

Revenue $m

Mar Jun Sep Dec Year
’26 658 673 — — —
’25 647 619 625 639 2,530
’24 589 596 606 640 2,431
’23 560 554 565 586 2,264
’22 531 531 526 547 2,135
’21 527 532 539 541 2,139
’20 516 502 528 533 2,080
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 88 85 — — —
’25 33 139 83 134 388
’24 85 78 91 165 417
’23 60 132 29 109 330
’22 101 57 52 100 310
’21 107 25 113 64 309
’20 89 188 125 87 489
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 71 70 — — —
’25 20 123 69 118 330
’24 72 69 77 152 371
’23 44 116 17 97 274
’22 89 45 39 82 255
’21 89 10 102 50 251
’20 69 176 114 72 432
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 4.84 5.13 — — —
’25 4.86 3.57 4.46 5.48 18.34
’24 4.24 4.65 5.00 6.02 19.89
’23 3.58 3.51 4.93 5.90 17.93
’22 4.22 4.40 3.78 4.13 16.53
’21 4.01 3.51 4.55 4.81 16.85
’20 3.38 5.01 4.14 6.96 19.48
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 124.77 158.60 243.68 265.08 330.01 403.00 430.16 481.99 512.12 408.42

Analyst estimates 2026–2028

Powerpack
High 164.07 251.00 335.99 445.10 543.81 560.00 530.72 596.91 654.62 623.61
People
People Employees 14,613 14,813 15,707 16,641 15,544 14,137 14,167 15,087 15,695 15,811
Revenue/emp, $m 0.11 0.11 0.11 0.12 0.13 0.15 0.15 0.15 0.15 0.16
Income, $m
Income, $m Revenue 1,577 1,667 1,783 1,939 2,080 2,139 2,135 2,264 2,431 2,530
Gross margin, % 29.26 30.97 31.13 31.85 33.73 35.98 35.84 35.28 35.14 32.54
EBT 177 117 240 262 396 350 330 350 399 356
EBT margin, % 11.23 7.01 13.44 13.50 19.04 16.38 15.44 15.47 16.43 14.06
Net income 109 98 206 220 319 269 250 273 302 265
Depreciation 37 37 40 46 57 59 60 61 63 65
Per share, $
Per share, $ Revenue 96.25 103.80 111.01 121.39 130.34 136.51 143.01 150.46 161.83 175.72
Earnings 6.64 6.11 12.80 13.77 20.02 17.14 16.72 18.11 20.10 18.42
Cash flow 8.26 10.12 17.88 18.86 30.67 19.69 20.76 21.95 27.79 26.97
Capex (2.43) (4.00) (3.29) (3.32) (3.58) (3.69) (3.68) (3.74) (3.08) (4.04)
Free cash flow 5.84 6.12 14.59 15.54 27.09 16.01 17.07 18.21 24.71 22.92
Book value 31.99 33.65 36.82 45.50 56.48 39.77 53.50 73.61 74.48 68.02
Shares, m 16 16 16 16 16 16 15 15 15 14
Valuation, ×
Valuation, × P/E 24.38 40.42 22.13 31.92 26.59 30.83 30.32 32.31 26.33 23.19
P/S 1.68 2.38 2.55 3.62 4.09 3.88 3.54 3.89 3.27 2.43
P/B 5.07 7.34 7.69 9.65 9.43 13.30 9.47 7.94 7.11 6.29
EV/Sales 1.74 2.43 2.60 3.69 4.07 3.97 3.56 3.81 3.24 2.45
EV/FCF 28.75 41.30 19.82 28.79 19.60 33.86 29.78 31.52 21.24 18.75
Cash, $m
Cash, $m Operating cash flow 135 162 287 301 489 309 310 330 417 388
Capex (40) (64) (53) (53) (57) (58) (55) (56) (46) (58)
Free cash flow 96 98 234 248 432 251 255 274 371 330
Balance, $m
Balance, $m Working capital (2) (17) (32) (72) 30 (72) (25) 189 109 15
Total debt 109 101 103 139 135 235 98 — — —
Net debt 93 90 98 133 (28) 202 23 (264) (178) (75)
Shareholders’ equity 524 540 591 727 901 623 799 1,108 1,119 979
Returns, %
Returns, % ROA 12.55 10.91 21.69 19.60 23.64 19.34 17.93 17.52 18.10 16.54
ROIC 18.09 11.21 22.08 18.72 27.88 25.98 26.11 25.22 24.35 23.36
ROE 20.97 18.45 36.33 33.37 39.25 35.23 35.11 28.59 27.12 25.28
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Chemed Corporation vs peers in Medical Care Facilities (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
FMS Fresenius Medical Care AG & Co. KGaA $11.8B 11.5× 12.5× +3.89% (above 0%: growing) +6.82% (above 0%: growing) +1.57% (above 0%: growing) 26.95% 9.58% Compare
UHS Universal Health Services, Inc. $11.0B 7.5× 6.1× +8.27% (above 0%: growing) +9.47% (above 0%: growing) −23.78% (below 0%: shrinking) 90.87% 11.14% Compare
ENSG The Ensign Group, Inc. $10.4B 26.9× 24.1× +17.33% (above 0%: growing) +16.22% (above 0%: growing) +12.24% (above 0%: growing) 16.65% 8.50% Compare
PACS PACS Group, Inc. $7.6B 27.6× 16.8× +9.07% (above 0%: growing) +45.45% (above 0%: growing) +220.51% (above 0%: growing) 17.07% 7.66% Compare
CHE Chemed Corporation $6.7B 25.7× 20.4× +8.80% (above 0%: growing) +42.78% (above 0%: growing) −43.51% (below 0%: shrinking) 32.90% 13.25%
CON Concentra Group Holdings Parent, Inc. $5.0B 24.9× 17.0× +10.03% (above 0%: growing) +45.71% (above 0%: growing) +91.62% (above 0%: growing) 31.70% 18.99% Compare
LFST LifeStance Health Group, Inc. $4.7B 88.3× 58.5× +26.08% (above 0%: growing) n/m +55.22% (above 0%: growing) 35.15% 7.04% Compare
OPCH Option Care Health, Inc. $4.7B 23.5× 14.1× +1.86% (above 0%: growing) +12.90% (above 0%: growing) +112.36% (above 0%: growing) 18.53% 5.90% Compare
NHC National HealthCare Corporation $3.9B 26.9× 8.4× +8.83% (above 0%: growing) +68.63% (above 0%: growing) −41.57% (below 0%: shrinking) 100.00% 11.99% Compare
Median of peers $6.3B 25.9× 15.5× +8.95% +16.22% +33.73% 29.33% 9.04%

All 55 Medical Care Facilities stocks →

Chemed Corporation (CHE) key facts

  • Concern: Net income was $265.2 million, or $18.42 per share (basic), a net margin of 10.5%.
  • Strength: Chemed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 4.06% from fiscal 2024.
  • Chemed Corporation (CHE) is a Medical Care Facilities company in the Healthcare sector, listed on the New York Stock Exchange.
  • As of October 16, 2026, CHE traded at $512.38, a market capitalization of $6.7 billion.
  • At that price the stock trades at 25.7× trailing-twelve-month earnings and 2.6× sales; its P/E is higher than 35% of its own readings over the past ten years.
  • Chemed Corporation pays an annual dividend of $2.50 per share, a yield of 0.49%, with a payout ratio of 12.6%.
  • Return on equity was 25.3% and debt-to-equity 0.17.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 11.69 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Chemed Corporation (CHE) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/CHE · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com